UnitedHealth Group reports Q3 2026 results on October 13, with Elevance following on October 21, Humana on November 6, and CVS on November 4. The most useful calls will separate current operating recovery from next-year positioning. For 2026, watch medical-cost performance, prior-period development, segment margins, and guidance. For 2027 and 2028, watch how management frames the newly confirmed Star Ratings' effect on quality-bonus economics.
UnitedHealth Group releases its Q3 2026 financial results on 10-13-2026, before the market opens. Elevance Health follows on 10-21-2026. CVS Health reports on 11-04-2026, and Humana on 11-06-2026. The sequence covers four of the largest publicly traded managed care organizations. Each call will be read against a common set of questions: how are medical costs tracking relative to 2026 benefit design assumptions, what does management expect from Q4, and how are they positioning for 2027 and 2028.
Q3 2026 adjusted EPS consensus stands at approximately $4.12 based on analyst estimates available prior to the report date [verify: confirm current Q3 2026 adjusted EPS consensus]. For context, UHG reported Q2 2026 adjusted EPS of $6.38 against a $4.94 consensus and issued full-year 2026 adjusted EPS guidance of $19.50 to $20.00 on 07-16-2026 [verify: confirm Q2 adjusted EPS figure and full-year guidance range].
Three questions drive the UHG read:
Medical-cost performance. UHG entered 2026 having provided full-year membership guidance that reflected deliberate pricing and benefit-design actions in its Medicare Advantage book. The question for Q3 is whether the MA book is performing within the medical cost ratios the company projected when it set those 2026 benefits.
Prior-period development. Q2 2026 results included favorable prior-period development that contributed to the EPS beat against consensus. Q3 calls that separate current-period medical cost performance from prior-period development provide a cleaner read on the underlying trajectory. Watch for management's characterization of reserve adequacy.
2026 full-year guidance. Whether management narrows, raises, or trims the $19.50 to $20.00 adjusted EPS range on the October 13 call indicates confidence in Q4 medical cost assumptions. A guidance raise signals that the benefit design is holding. A trim raises questions about Q4 utilization expectations.
Elevance's 2026 narrative has centered on margin recovery after MLR pressure in prior periods. Whether that recovery is materializing in reported results is the central question for the October 21 call.
Medicaid rate adequacy. Medicaid is the segment where Elevance's margin exposure is most visible. Management's commentary on rate adequacy in key states, the timing of rate adjustments, and the outlook for 2027 contract renewals will be more informative than any single quarter's reported ratio.
Commercial performance. Separate Elevance's commercial medical-benefit ratio from its government business when assessing the overall ratio. Movements in the commercial segment may reflect different dynamics than the government business and should not be used to characterize the MA or Medicaid position alone.
Full-year guidance. Whether Elevance affirms or revises its 2026 outlook on October 21 provides a final-quarter read on whether the margin recovery thesis holds through year-end.
Humana's 2025 earnings narrative was significantly shaped by the 2026 Star Ratings cycle, in which the company's quality bonus eligibility declined substantially. [verify: confirm Humana's specific 2026 Star Ratings distribution from company disclosures or CMS data].
The 2027 Star Ratings, released 10-08-2026, appear to show a meaningful Humana improvement based on market reactions [verify: confirm Humana's specific 2027 contract-level ratings from the CMS October 8 data file]. If confirmed, management will frame the November 6 call around the 2028 quality-bonus payment trajectory, and what it means for 2027 benefit design and AEP enrollment positioning.
The specific number to track: what share of Humana's projected 2027 MA enrollment will be in contracts rated four stars or above? The enrollment-weighted share in qualifying contracts determines the 2028 quality bonus and rebate percentage that feeds into 2028 bid economics. Enrollment share summarizes exposure to qualifying contracts; the actual payment and rebate economics depend on each contract's rating, county benchmarks, bid, and enrollment distribution.
Also watch Humana's characterization of medical-cost performance. The company's reported medical benefit ratio reflects a mix of business that includes MA, Medicaid managed care, and commercial segments. Read it alongside disclosed business mix, prior-period development, and management's explanation of the current medical-cost environment.
CVS presents the most complex earnings structure. Pharmacy and Caremark segments introduce revenue and cost dynamics that can mask the health plan performance. Isolate the Health Care Benefits segment when assessing Aetna's position.
The Health Care Benefits segment's medical-benefit ratio is not an Aetna MA-only metric. It moves because of changes across all lines of business within the segment, not only the Medicare Advantage book. Read the segment ratio alongside disclosed business mix, prior-period development, and CVS's explanation of medical-cost performance. MA-specific membership and commentary, when management provides it, is a more direct signal on the senior business.
CVS reports on 11-04-2026, during the Annual Enrollment Period. Management's commentary on 2027 AEP positioning and Aetna MA membership expectations will be particularly timely given that AEP closes 12-07-2026.
The most useful earnings calls will separate three distinct questions:
Current operating performance. Medical-cost performance relative to each carrier's own projections, the contribution of prior-period development, segment margins by line of business, and Q4 or full-year guidance. Evidence of improvement should include these components, not a single reported ratio in isolation.
2027 membership and pricing. MA product changes, benefit restructuring, market exits, and pricing adequacy for the 2027 plan year that is now in its enrollment period.
2028 quality-bonus economics. How each company quantifies the confirmed 2027 Star Ratings' effect on 2028 quality-bonus payment eligibility and what that means for 2028 benefit design and bid assumptions. The 2027 ratings determine 2028 quality-bonus payments; that connection has direct implications for how each company models its 2028 revenue and margin assumptions.
Sources: UnitedHealth Group earnings release date confirmed via Business Wire, 09-15-2026; Elevance Health Q3 2026 earnings date, company announcement 10-05-2026; CVS Health and Humana Q3 2026 earnings dates from investor relations.
This is analysis, not investment advice. Continuum does not make recommendations to buy or sell securities.
Discover how Addie helps health systems, post-acute providers, and payers improve throughput, reduce avoidable days, and deliver better transitions of care.
Get Started